PLK1 and prostate carcinoma: Clinically, PLK1 is established as a prognostic marker and a therapeutic target for the majority of solid, blood, and metastatic cancers, including gastric cancer 19, NSCLC 20, colorectal cancer 48, and prostate cancer 49.